Drug class
Humanised monoclonal antibody; vascular endothelial growth factor A (VEGF-A) inhibitor
Mechanism of action
Binds VEGF-A and prevents it from interacting with VEGF receptors on endothelial cells, inhibiting angiogenesis and reducing tumour-associated vascular permeability. Product-specific biosimilar status does not change the bevacizumab active moiety.
General use cases
- Oncology indications for bevacizumab products are tumour- and combination-specific, including selected colorectal, lung, renal, ovarian and cervical cancers; assign only the indications listed in the current product-specific biosimilar label and jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
